Tango Therapeutics trades 2,136 contracts. The company has the following event: Conference Call to Discuss Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers on Oct 23, 2025.
News: Tango Therapeutics Announces $225 Million Financing
